WiCell and the UKSCB aim to reduce costs to researchers by making a panel of each institutions most popular lines available through each center. (press release)
The UKSCB has completed Due Diligence assessment of the first 12 cell lines intend for human application by their depositors. These have been assessed as complying with HTA directions allowing the UKSCB to accession and begin banking these cell lines in the near future. Read more...
The UK Stem Cell Bank (UKSCB) has developed a wide ranging portfolio of interactions in academic research and industry, both in the UK and abroad. Through these interactions the UKSCB has developed a significant reputation for the quality of its work in providing underpinning support based on expertise it has developed in stem cell culture, preservation, characterisation and cryopreservation.
Its independent and neutral role in the area of regenerative medicine and other applications of stem cell lines, has been a key factor in securing this unique position in the field. Currently, the UKSCB has a number of ways in which it engages with the stem cell and cell therapy communities, including contribution to a number of international toxicology projects (e.g. ESNATS, ToxBank, Scr&Tox), early development of new technologies for cell therapy and regulatory support (e.g. hESCreg, International Stem, Cell banking Initiative). Examples of these and other interactions are given on the following webpages, and further information and contacts for new collaborations, can be obtained direct from the UKSCB via our enquiries email: